Molecular markers for cancer prognosis and treatment: Have we struck gold?

Cancer Letters

Volumn 327, Issue 1-2, 2012, Pages 142-152

  Nowsheen, Somaira ^a   Aziz, Khaled ^b   Panayiotidis, Mihalis I ^c   Georgakilas, Alexandros G ^d,e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF IOANNINA   (Greece)

^d EAST CAROLINA UNIVERSITY   (United States)

^e NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

Biomarkers; Cancer; DNA damage; Epigenetics; Inflammation; Personalized treatment

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHEMOKINE; CHEMOKINE CCL18; CXCL1 CHEMOKINE; CYTOKERATIN; CYTOKERATIN 19 FRAGMENT; DNA DEPENDENT PROTEIN KINASE; DOCKING PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GAMMA HISTONE H2AX; HISTONE H2AX; K RAS PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN KU80; PYRUVATE KINASE; RAD51 PROTEIN; TUMOR M2 PYRUVATE KINASE; TUMOR MARKER; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SCREENING; CANCER THERAPY; CARCINOGENESIS; COLON CANCER; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; EPIGENETICS; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC SCREENING; GENOMICS; HEAD AND NECK CANCER; HUMAN; LEUKEMIA; LUNG CANCER; MASS SPECTROMETRY; METABOLOMICS; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; WART VIRUS;

EID: 84867449930     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.11.022     Document Type: Review

References (162)

1. Franco R., Schoneveld O., Georgakilas A.G., Panayiotidis M.I. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett. 2008, 266:6-12.
2. Kryston T.B., Georgiev A., Georgakilas A.G. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat. Res. 2011, 711:193-201.
3. Negrini S., Gorgoulis V.G., Halazonetis T.D. Genomic instability - an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 2010, 11:220-228.
4. Smith J.S., Tachibana I., Passe S.M., Huntley B.K., Borell T.J., Iturria N., O'Fallon J.R., Schaefer P.L., Scheithauer B.W., James C.D., Buckner J.C., Jenkins R.B., Mutation P.T.E.N., Amplification E.G.F.R. And outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl Cancer Inst. 2001, 93:1246-1256.
5. Sedelnikova O.A., Redon C.E., Dickey J.S., Nakamura A.J., Georgakilas A.G., Bonner W.M. Role of oxidatively induced DNA lesions in human pathogenesis. Mutat. Res. 2010, 704:152-159.
6. Martin O.A., Redon C., Nakamura A.J., Dickey J.S., Georgakilas A.G., Bonner W.M. Systemic DNA damage related to cancer. Cancer Res. 2011, 71:3437-3441.
7. Sawyers C.L. The cancer biomarker problem. Nature 2008, 452:548-552.
8. Georgakilas A.G. From chemistry of DNA damage to repair and biological significance. Comprehending the future. Mutat. Res. 2011, 711:1-2.
9. Brugmann A., Sorensen B.S. Identifying responders to trastuzumab therapy in breast cancer. Future Oncol. 2011, 7:767-773.
10. O'Shaughnessy J., Osborne C., Pippen J.E., Yoffe M., Patt D., Rocha C., Koo I.C., Sherman B.M., Bradley C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 2011, 364:205-214.
11. Favilla V., Cimino S., Madonia M., Morgia G. New advances in clinical biomarkers in testis cancer. Front Biosci. (Elite Ed) 2009, 2:456-477.
12. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., Minasian L.M., Ford L.G., Lippman S.M., Crawford E.D., Crowley J.J., Coltman C.A. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0ng per milliliter. N. Engl. J. Med. 2004, 350:2239-2246.
13. Barkin J. PSA and the family physician. Can. J. Urol. 2011, 18(Suppl.):20-23.
14. Bjartell A., Montironi R., Berney D.M., Egevad L. Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers. Acta Oncol. 2011, 50(Suppl. 1):76-84.
15. Carpi A., Mechanick J.I., Saussez S., Nicolini A. Thyroid tumor marker genomics and proteomics: diagnostic and clinical implications. J. Cell. Physiol. 2010, 224:612-619.
16. Gilligan T.D., Seidenfeld J., Basch E.M., Einhorn L.H., Fancher T., Smith D.C., Stephenson A.J., Vaughn D.J., Cosby R., Hayes D.F. American society of clinical oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors. J. Clin. Oncol. 2010, 28:3388-3404.
17. Nikiforov Y.E. Molecular diagnostics of thyroid tumors. Arch. Pathol. Lab. Med. 2011, 135:569-577.
18. Menon U., Gentry-Maharaj A., Jacobs I. Ovarian cancer screening and mortality. J. Am. Med. Assoc. 2011, 306:1544. (author reply 1544-1545).
19. Nakamura K., Imafuku N., Nishida T., Niwa I., Joja I., Hongo A., Kodama J., Hiramatsu Y. Measurement of the minimum apparent diffusion coefficient (ADCmin) of the primary tumor and CA125 are predictive of disease recurrence for patients with endometrial cancer. Gynecol. Oncol. 2011.
20. Wasan H.S., Springett G.M., Chodkiewicz C., Wong R., Maurel J., Barone C., Rosbrook B., Ricart A.D., Kim S., Spano J.P. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. Br. J. Cancer 2009, 101:1162-1167.
21. Brewis I.A., Brennan P. Proteomics technologies for the global identification and quantification of proteins. Adv. Protein Chem. Struct. Biol. 2010, 80:1-44.
22. Chiou S.H., Wu C.Y. Clinical proteomics: current status, challenges, and future perspectives. Kaohsiung J. Med. Sci. 2010, 27:1-14.
23. Hanash S.M., Pitteri S.J., Faca V.M. Mining the plasma proteome for cancer biomarkers. Nature 2008, 452:571-579.
24. Alderton G.K. Proteomics: biomarkers on a nanoscale. Nat. Rev. Cancer 2009, 9:382-383.
25. Solit D.B., Mellinghoff I.K. Tracing cancer networks with phosphoproteomics. Nat. Biotechnol. 2010, 28:1028-1029.
26. Eyrich B., Sickmann A., Zahedi R.P. Catch me if you can: mass spectrometry-based phosphoproteomics and quantification strategies. Proteomics 2011, 11:554-570.
27. Grimsrud P.A., Swaney D.L., Wenger C.D., Beauchene N.A., Coon J.J. Phosphoproteomics for the masses. ACS Chem. Biol. 2010, 5:105-119.
28. Lemeer S., Heck A.J. The phosphoproteomics data explosion. Curr. Opin. Chem. Biol. 2009, 13:414-420.
29. Asiago V.M., Alvarado L.Z., Shanaiah N., Gowda G.A., Owusu-Sarfo K., Ballas R.A., Raftery D. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 2010, 70:8309-8318.
30. Catchpole G., Platzer A., Weikert C., Kempkensteffen C., Johannsen M., Krause H., Jung K., Miller K., Willmitzer L., Selbig J., Weikert S. Metabolic profiling reveals key metabolic features of renal cell carcinoma. J. Cell. Mol. Med. 2009, 15:109-118.
31. Nordstrom A., Lewensohn R. Metabolomics: moving to the clinic. J. Neuroimmune Pharmacol. 2009, 5:4-17.
32. Tainsky M.A. Genomic and proteomic biomarkers for cancer: a multitude of opportunities. Biochim. Biophys. Acta 2009, 1796:176-193.
33. Roberts M.J., Schirra H.J., Lavin M.F., Gardiner R.A. Metabolomics: a novel approach to early and noninvasive prostate cancer detection. Korean J. Urol. 2011, 52:79-89.
34. Griffin J.L., Shockcor J.P. Metabolic profiles of cancer cells. Nat. Rev. Cancer 2004, 4:551-561.
35. Geradts J., Bean S.M., Bentley R.C., Barry W.T. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest. 2010, 28:969-977.
36. Kohler C., Barekati Z., Radpour R., Zhong X.Y. Cell-free DNA in the circulation as a potential cancer biomarker. Anticancer Res. 2011, 31:2623-2628.
37. Sikaroodi M., Galachiantz Y., Baranova A. Tumor markers: the potential of "omics" approach. Curr. Mol. Med. 2010, 10:249-257.
38. Spielmann N., Wong D.T. Saliva: diagnostics and therapeutic perspectives. Oral Dis. 2010, 17:345-354.
39. Bockmann B., Grill H.J., Giesing M. Molecular characterization of minimal residual cancer cells in patients with solid tumors. Biomol. Eng. 2001, 17:95-111.
40. Le Roux E., Gormally E., Hainaut P. Somatic mutations in human cancer: applications in molecular epidemiology. Rev. Epidemiol. Sante Publique 2005, 53:257-266.
41. Vlacich G., Roe C., Webb G.C. Technology insight: microarrays - research and clinical applications. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3:594-605.
42. Hayashi N., Yamauchi H. Role of circulating tumor cells and disseminated tumor cells in primary breast cancer. Breast Cancer 2011, 10.1007/s12282-12011-10282-12285.
43. Valmori D., Qian F., Ayyoub M., Renner C., Merlo A., Gnjatic S., Stockert E., Driscoll D., Lele S., Old L.J., Odunsi K. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin. Cancer Res. 2006, 12:398-404.
44. Murakami K., Mitomi H., Yamashita K., Tanabe S., Saigenji K., Okayasu I. P53, but not c-Ki-ras, mutation and down-regulation of p21WAF1/CIP1 and cyclin D1 are associated with malignant transformation in gastric hyperplastic polyps. Am. J. Clin. Pathol. 2001, 115:224-234.
45. Shah N.G., Trivedi T.I., Tankshali R.A., Goswami J.V., Jetly D.H., Shukla S.N., Shah P.M., Verma R.J. Prognostic significance of molecular markers in oral squamous cell carcinoma: a multivariate analysis. Head Neck 2009, 31:1544-1556.
46. Ebos J.M.L., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
47. Patel A.S., Allen J.E., Dicker D.T., Peters K.L., Sheehan J.M., Glantz M.J., El-Deiry W.S. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget 2011.
48. Sanz-Pamplona R., Aragues R., Driouch K., Martin B., Oliva B., Gil M., Boluda S., Fernandez P.L., Martinez A., Moreno V., Acebes J.J., Lidereau R., Reyal F., Van de Vijver M.J., Sierra A. Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2+ and ErbB-2- primary breast tumors. Am. J. Pathol. 2011, 179:564-579.
49. Cakir E., Yilmaz A., Demirag F., Oguztuzun S., Sahin S., Yazici U.E., Aydin M. Prognostic significance of micropapillary pattern in lung adenocarcinoma and expression of apoptosis-related markers: caspase-3, bcl-2, and p53. APMIS 2011, 119:574-580.
50. Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer 2011, 117:3889-3899.
51. Hartge P. Designing early detection programs for ovarian cancer. J. Natl. Cancer Inst. 2009, 102:3-4.
52. Gao J., Zhu F., Lv S., Li Z., Ling Z., Gong Y., Jie C., Ma L. Identification of pancreatic juice proteins as biomarkers of pancreatic cancer. Oncol. Rep. 2010, 23:1683-1692.
53. Ziech D., Franco R., Pappa A., Malamou-Mitsi V., Georgakila S., Georgakilas A.G., Panayiotidis M.I. The role of epigenetics in environmental and occupational carcinogenesis. Chem. Biol. Interact. 2010, 188:334-339.
54. Ziech D., Franco R., Georgakilas A.G., Georgakila S., Malamou-Mitsi V., Schoneveld O., Pappa A., Panayiotidis M.I. The role of reactive oxygen species and oxidative stress in environmental carcinogenesis and biomarker development. Chem. Biol. Interact. 2010, 188:334-339.
55. Wansom D., Light E., Worden F., Prince M., Urba S., Chepeha D.B., Cordell K., Eisbruch A., Taylor J., D'Silva N., Moyer J., Bradford C.R., Kurnit D., Kumar B., Carey T.E., Wolf G.T. Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch. Otolaryngol. Head Neck Surg. 2010, 136:1267-1273.
56. Albers A., Abe K., Hunt J., Wang J., Lopez-Albaitero A., Schaefer C., Gooding W., Whiteside T.L., Ferrone S., DeLeo A., Ferris R.L. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res. 2005, 65:11146-11155.
57. Sirianni N., Ha P.K., Oelke M., Califano J., Gooding W., Westra W., Whiteside T.L., Koch W.M., Schneck J.P., DeLeo A., Ferris R.L. Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2004, 10:6929-6937.
58. Sirianni N., Wang J., Ferris R.L. Antiviral activity of Cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity. Oral Oncol. 2005, 41:423-428.
59. Kumar B., Cordell K.G., Lee J.S., Prince M.E., Tran H.H., Wolf G.T., Urba S.G., Worden F.P., Chepeha D.B., Teknos T.N., Eisbruch A., Tsien C.I., Taylor J.M., D'Silva N.J., Yang K., Kurnit D.M., Bradford C.R., Carey T.E. Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69:S109-111.
60. Kumar B., Cordell K.G., Lee J.S., Worden F.P., Prince M.E., Tran H.H., Wolf G.T., Urba S.G., Chepeha D.B., Teknos T.N., Eisbruch A., Tsien C.I., Taylor J.M., D'Silva N.J., Yang K., Kurnit D.M., Bauer J.A., Bradford C.R., Carey T.E. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J. Clin. Oncol. 2008, 26:3128-3137.
61. Sisk E.A., Soltys S.G., Zhu S., Fisher S.G., Carey T.E., Bradford C.R. Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck 2002, 24:841-849.
62. Georgakilas A.G. Processing of DNA damage clusters in human cells: current status of knowledge. Mol. BioSyst. 2008, 4:30-35.
63. Eccles L.J., Lomax M.E., O'Neill P. Hierarchy of lesion processing governs the repair, double-strand break formation and mutability of three-lesion clustered DNA damage. Nucleic Acids Res. 2010, 38:1123-1134.
64. Malyarchuk S., Brame K.L., Youngblood R., Shi R., Harrison L. Two clustered 8-oxo-7, 8-dihydroguanine (8-oxodG) lesions increase the point mutation frequency of 8-oxodG, but do not result in double strand breaks or deletions in Escherichia coli. Nucleic Acids Res. 2004, 32:5721-5731.
65. Radford I.R., Lobachevsky P.N. Clustered DNA lesion sites as a source of mutations during human colorectal tumourigenesis. Mutat. Res. 2008, 646:60-68.
66. Singleton B.K., Griffin C.S., Thacker J. Clustered DNA damage leads to complex genetic changes in irradiated human cells. Cancer Res. 2002, 62:6263-6269.
67. Hair J.M., Terzoudi G.I., Hatzi V.I., Lehockey K.A., Srivastava D., Wang W., Pantelias G.E., Georgakilas A.G. BRCA1 role in the mitigation of radiotoxicity and chromosomal instability through repair of clustered DNA lesions. Chem. Biol. Interact. 2010, 188:350-358.
68. Asaithamby A., Hu B., Chen D.J. Unrepaired clustered DNA lesions induce chromosome breakage in human cells. Proc. Natl. Acad. Sci. USA 2011, 10.1073/pnas.1016045108.
69. Pastukh V.M., Zhang L., Ruchko M.V., Gorodnya O., Bardwell G.C., Tuder R.M., Gillespie M.N. Oxidative DNA damage in lung tissue from patients with COPD is clustered in functionally significant sequences. Int. J. Chronic Obstruct. Pulm. Dis. 2011, 6:209-217.
70. Nowsheen S., Wukovich R.L., Aziz K., Kalogerinis P.T., Richardson C.C., Panayiotidis M.I., Bonner W.M., Sedelnikova O.A., Georgakilas A.G. Accumulation of oxidatively induced clustered DNA lesions in human tumor tissues. Mutat. Res. 2009, 674:131-136.
71. Redon C., Dickey J.S., Nakamura A., Kareva I., Naf D., Nowsheen S., Kryston T.B., Bonner W.M., Georgakilas A.G., Sedelnikova O.A. Tumors induce complex DNA damage in distant proliferative tissues in vivo. Proc. Natl. Acad. Sci. USA 2010, 107:17992-17997.
72. Redon C., Dickey J.S., Nakamura A.J., Naf D., Nowsheen S., Kalogerinis P., Bonner W.M., Georgakilas A.G., Sedelnikova O.A. Tumors induce complex DNA damage in distant proliferative tissues in vivo. Cancer Res. 2010, 70(8 Suppl.):2287-2288.
73. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., Ditullio R.A., Kastrinakis N.G., Levy B., Kletsas D., Yoneta A., Herlyn M., Kittas C., Halazonetis T.D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
74. Mladenov E., Iliakis G. Induction and repair of DNA double strand breaks: The increasing spectrum of non-homologous end joining pathways. Mutat. Res. 2011, 711:61-72.
75. Eot-Houllier G., Gonera M., Gasparutto D., Giustranti C., Sage E. Interplay between DNA N-glycosylases/AP lyases at multiply damaged sites and biological consequences. Nucleic Acids Res. 2007, 35:3355-3366.
76. Rodrigue A., Lafrance M., Gauthier M.C., McDonald D., Hendzel M., West S.C., Jasin M., Masson J.Y. Interplay between human DNA repair proteins at a unique double-strand break in vivo. EMBO J. 2006, 25:222-231.
77. Georgakilas A.G. Detection of clustered DNA lesions: Biological and clinical applications. World J. Biol. Chem. 2011, 2:173-176.
78. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 2003, 3:155-168.
79. Xing J., Wu X., Vaporciyan A.A., Spitz M.R., Gu J. Prognostic significance of ataxia-telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer. Cancer 2008, 112:2756-2764.
80. Ye C., Cai Q., Dai Q., Shu X.-o., Shin A., Gao Y.-T., Zheng W. Expression patterns of the ATM gene in mammary tissues and their associations with breast cancer survival. Cancer 2007, 109:1729-1735.
81. Shrivastav M., De Haro L.P., Nickoloff J.A. Regulation of DNA double-strand break repair pathway choice. Cell Res. 2008, 18:134-147.
82. Sliwinski T., Krupa R., Majsterek I., Rykala J., Kolacinska A., Morawiec Z., Drzewoski J., Zadrozny M., Blasiak J. Polymorphisms of the BRCA2 and RAD51 genes in breast cancer. Breast Cancer Res. Treat. 2005, 94:105-109.
83. Peralta-Leal A., Rodríguez-Vargas J.M., Aguilar-Quesada R., Rodríguez M.I., Linares J.L., de Almodóvar M.R., Oliver F.J. PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases. Free Radical Biol. Med. 2009, 47:13-26.
84. Hegan D.C., Lu Y., Stachelek G.C., Crosby M.E., Bindra R.S., Glazer P.M. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc. Natl. Acad. Sci. USA 2011, 107:2201-2206.
85. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., Ashworth A., Carmichael J., Kaye S.B., Schellens J.H., de Bono J.S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361:123-134.
86. Lai T.C., Chow K.C., Lin T.Y., Chiang I.P., Fang H.Y., Chen C.Y., Ho S.P. Expression of 53BP1 as a cisplatin-resistant marker in patients with lung adenocarcinomas. Oncol. Rep. 2010, 24:321-328.
87. Bouwman P., Aly A., Escandell J.M., Pieterse M., Bartkova J., van der Gulden H., Hiddingh S., Thanasoula M., Kulkarni A., Yang Q., Haffty B.G., Tommiska J., Blomqvist C., Drapkin R., Adams D.J., Nevanlinna H., Bartek J., Tarsounas M., Ganesan S., Jonkers J. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 2010, 17:688-695.
88. Liu S.K., Coackley C., Krause M., Jalali F., Chan N., Bristow R.G. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother. Oncol. 2008, 88:258-268.
89. Nowsheen S., Bonner J.A., Yang E.S. The poly (ADP-Ribose) polymerase inhibitor ABT-888 reduces nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother. Oncol. 2011.
90. Löser D.A., Shibata A., Shibata A.K., Woodbine L.J., Jeggo P.A., Chalmers A.J. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol. Cancer Ther. 2011, 9:1775-1787.
91. von Minckwitz G., Müller B.M., Loibl S., Budczies J., Hanusch C., Darb-Esfahani S., Hilfrich J.r., Weiss E., Huober J., Blohmer J.U., du Bois A., Zahm D.-M., Khandan F., Hoffmann G., Gerber B., Eidtmann H., Fend F., Dietel M., Mehta K., Denkert C. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J. Clin. Oncol. 2011, 29:2150-2157.
92. Alexander B.M., Sprott K., Farrow D.A., Wang X., D'Andrea A.D., Schnitt S.J., Collins L.C., Weaver D.T., Garber J.E. DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. Clin. Cancer Res. 2010, 16:5796-5804.
93. Torres M., Raju U., Molkentine D., Riesterer O., Milas L., Ang K. AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest. New Drugs 2011, 29:554-561.
94. Toulany M., Minjgee M., Kehlbach R., Chen J., Baumann M., Rodemann H.P. ErbB2 expression through heterodimerization with erbB1 is necessary for ionizing radiation- but not EGF-induced activation of Akt survival pathway. Radiother. Oncol. 2010, 97:338-345.
95. Li L., Wang H., Yang E.S., Arteaga C.L., Xia F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res. 2008, 68:9141-9146.
96. Dittmann K., Mayer C., Rodemann H. Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function. Strahlenther. Onkol. 2010, 186:1-6.
97. Friedmann B., Caplin M., Hartley J.A., Hochhauser D. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor Gefitinib (ZD1839). Clin. Cancer Res. 2004, 10:6476-6486.
98. Dittmann K., Mayer C., Fehrenbacher B., Schaller M., Raju U., Milas L., Chen D.J., Kehlbach R., Rodemann H.P. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J. Biol. Chem. 2005, 280:31182-31189.
99. Golding S.E., Morgan R.N., Adams B.R., Hawkins A.J., Povirk L.F., Valerie K. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol. Ther. 2009, 8:730-738.
100. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995, 19:183-232.
101. Baselga J., Swain S.M. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin. Breast Cancer 2010, 10:489-491.
102. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5:341-354.
103. Chung C.H., Zhang Q., Hammond E.M., Trotti A.M., Wang H., Spencer S., Zhang H.-Z., Cooper J., Jordan R., Rotman M.H., Ang K.K. Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2011, 81:331-338.
104. Lee H.J., Xu X., Choe G., Chung D.H., Seo J.-W., Lee J.H., Lee C.-T., Jheon S., Sung S.-W., Chung J.-H. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer 2010, 68:375-382.
105. Janjigian Y.Y., Azzoli C.G., Krug L.M., Pereira L.K., Rizvi N.A., Pietanza M.C., Kris M.G., Ginsberg M.S., Pao W., Miller V.A., Riely G.J. Phase I/II Trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin. Cancer Res. 2011, 17:2521-2527.
106. Jackman D.M., Yeap B.Y., Sequist L.V., Lindeman N., Holmes A.J., Joshi V.A., Bell D.W., Huberman M.S., Halmos B., Rabin M.S., Haber D.A., Lynch T.J., Meyerson M., Johnson B.E., Jänne P.A. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin. Cancer Res. 2006, 12:3908-3914.
107. Rizvi N.A., Rusch V., Pao W., Chaft J.E., Ladanyi M., Miller V.A., Krug L.M., Azzoli C.G., Bains M., Downey R., Flores R., Park B., Singh B., Zakowski M., Heelan R.T., Shen R., Kris M.G. Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clin. Cancer Res. 2011, 17:3500-3506.
108. Molaei M., Pejhan S., Nayer B.N., Moradi A., Ghiasi S., Zali M.R. Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: correlation with survival and clinicopathological findings. Eur. J. Gastroenterol. Hepatol. 2009, 21:289-293.
109. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 1998, 273:5858-5868.
110. Burma S., Chen B.P., Murphy M., Kurimasa A., Chen D.J. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J. Biol. Chem. 2001, 276:42462-42467.
111. Bonner W.M., Redon C.E., Dickey J.S., Nakamura A.J., Sedelnikova O.A., Solier S., Pommier Y. [gamma]H2AX and cancer. Nat. Rev. Cancer 2008, 8:957-967.
112. Sedelnikova O.A., Bonner W.M. GammaH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle 2006, 5:231-240.
113. Kinders R.J., Hollingshead M., Lawrence S., Ji J., Tabb B., Bonner W.M., Pommier Y., Rubinstein L., Evrard Y.A., Parchment R.E., Tomaszewski J., Doroshow J.H. Development of a validated immunofluorescence assay for γ-H2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. Clin. Cancer Res. 2010, 16:5447-5457.
114. Redon C.E., Nakamura A.J., Zhang Y.-W., Ji J., Bonner W.M., Kinders R.J., Parchment R.E., Doroshow J.H., Pommier Y. Histone H2AX and poly(ADP-Ribose) as clinical pharmacodynamic biomarkers. Clin. Cancer Res. 2010, 16:4532-4542.
115. Collis S.J., DeWeese T.L., Jeggo P.A., Parker A.R. The life and death of DNA-PK. Oncogene 2004, 24:949-961.
116. Kim S.H., Kim D., Han J.S., Jeong C.S., Chung B.S., Kang C.D., Li G.C. Ku autoantigen affects the susceptibility to anticancer drugs. Cancer Res. 1999, 59:4012-4017.
117. Chang H.W., Kim S.Y., Yi S.-L., Son S.-H., Song D.Y., Moon S.Y., Kim J.H., Choi E.K., Ahn S.D., Shin S.S., Lee K.K., Lee S.-w. Expression of Ku80 correlates with sensitivities to radiation in cancer cell lines of the head and neck. Oral Oncol. 2006, 42:979-986.
118. Moeller B.J., Yordy J.S., Williams M.D., Giri U., Raju U., Molkentine D.P., Byers L.A., Heymach J.V., Story M.D., Lee J.J., Sturgis E.M., Weber R.S., Garden A.S., Ang K.K., Schwartz D.L. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin. Cancer Res. 2011, 17:2035-2043.
119. Yin J., Li J., Ma Y., Guo L., Wang H., Vogel U. The DNA repair gene ERCC2/XPD polymorphism Arg 156Arg (A22541C) and risk of lung cancer in a Chinese population. Cancer Lett. 2005, 223:219-226.
120. Garcãa-Closas M., Malats N.r., Real F.X., Welch R., Kogevinas M., Chatterjee N., Pfeiffer R., Silverman D., Dosemeci M., Tardã3n A., Serra C., Carrato A., Garcãa-Closas R., Castaã±o-Vinyals G., Chanock S., Yeager M., Rothman N. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol. Biomarkers Prev. 2006, 15:536-542.
121. Worrillow L., Roman E., Adamson P.J., Kane E., Allan J.M., Lightfoot T.J. Polymorphisms in the nucleotide excision repair gene ERCC2/XPD and risk of non-Hodgkin lymphoma. Cancer Epidemiol. 2009, 33:257-260.
122. Wrensch M., Kelsey K.T., Liu M., Miike R., Moghadassi M., Sison J.D., Aldape K., McMillan A., Wiemels J., Wiencke J.K. ERCC1 and ERCC2 polymorphisms and adult glioma. Neuro Oncol. 2005, 7:495-507.
123. Pan J., Lin J., Izzo J.G., Liu Y., Xing J., Huang M., Ajani J.A., Wu X. Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway. Carcinogenesis 2009, 30:785-792.
124. Doherty J.A., Weiss N.S., Fish S., Fan W., Loomis M.M., Sakoda L.C., Rossing M.A., Zhao L.P., Chen C. Polymorphisms in nucleotide excision repair genes and endometrial cancer risk. Cancer Epidemiol. Biomarkers Prev. 2011, 20:1873-1882.
125. Martin L.P., Hamilton T.C., Schilder R.J. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 2008, 14:1291-1295.
126. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
127. Bonecchi R., Locati M., Mantovani A. Chemokines and cancer: a fatal attraction. Cancer Cell 2011, 19:434-435.
128. Chen J., Yao Y., Gong C., Yu F., Su S., Chen J., Liu B., Deng H., Wang F., Lin L., Yao H., Su F., Anderson Karenâ S., Liu Q., Ewen Markâ E., Yao X., Song E. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 2011, 19:541-555.
129. Wang Q., Li D., Zhang W., Tang B.L., Li Q.Q., Li L. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses. Int. J. Biol. Markers 2011, 10.5301/JBM.2011.8616.
130. Fernet M., Hall J. Genetic biomarkers of therapeutic radiation sensitivity. DNA Repair (Amst) 2004, 3:1237-1243.
131. Riesterer O., Milas L., Ang K.K. Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. J. Clin. Oncol. 2007, 25:4075-4083.
132. Das A.K., Bell M.H., Nirodi C.S., Story M.D., Minna J.D. Radiogenomics predicting tumor responses to radiotherapy in lung cancer. Semin. Radiat. Oncol. 2010, 20:149-155.
133. Kuremsky J.G., Tepper J.E., McLeod H.L. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74:673-688.
134. Smith D.S., Humphrey P.A., Catalona W.J. The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience. Cancer 1997, 80:1852-1856.
135. Andriole G.L., Grubb R.L., Buys S.S., Chia D., Church T.R., Fouad M.N., Gelmann E.P., Kvale P.A., Reding D.J., Weissfeld J.L., Yokochi L.A., Crawford E.D., O'Brien B., Clapp J.D., Rathmell J.M., Riley T.L., Hayes R.B., Kramer B.S., Izmirlian G., Miller A.B., Pinsky P.F., Prorok P.C., Gohagan J.K., Berg C.D. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 2009, 360:1310-1319.
136. Andersson M., Lidbrink E., Bjerre K., Wist E., Enevoldsen K., Jensen A.B., Karlsson P., Tange U.B., Sorensen P.G., Moller S., Bergh J., Langkjer S.T. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J. Clin. Oncol. 2010, 29:264-271.
137. Burris H.A., Rugo H.S., Vukelja S.J., Vogel C.L., Borson R.A., Limentani S., Tan-Chiu E., Krop I.E., Michaelson R.A., Girish S., Amler L., Zheng M., Chu Y.W., Klencke B., O'Shaughnessy J.A. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 2010, 29:398-405.
138. Torrisi R., Cardillo A., Cancello G., Dellapasqua S., Balduzzi A., Ghisini R., Luini A., Veronesi P., Viale G., Goldhirsch A., Colleoni M. Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer. Clin. Breast Cancer 2010, 10:483-488.
139. Gion M., Mione R., Leon A.E., Lüftner D., Molina R., Possinger K., Robertson J.F. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur. J. Cancer 2001, 37:355-363.
140. Cassol L., Silveira Graudenz M., Zelmanowicz A., Cancela A., Werutsky G., Rovere R.K., Garicochea B. Basal-like immunophenotype markers and prognosis in early breast cancer. Tumori 2011, 96:966-970.
141. Mulligan A.M., Pinnaduwage D., Bane A.L., Bull S.B., O'Malley F.P., Andrulis I.L. CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry. Cancer 2011, 117:1350-1359.
142. Fiaccavento S., Simone G. Cytology of indeterminate cases (C3). Can this diagnostic class be improved?. Pathologica 2011, 102:409-413.
143. Somlo G., Lau S.K., Frankel P., Hsieh H.B., Liu X., Yang L., Krivacic R., Bruce R.H. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res. Treat. 2011, 128:155-163.
144. Tolles J., Bai Y., Baquero M., Harris L.N., Rimm D.L., Molinaro A.M. Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma. Breast Cancer Res. 2011, 13:R51.
145. Roukos D.H., Ziogas D.E., Katsios C. Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks. Expert Rev. Anticancer Ther. 2010, 10:1187-1195.
146. Herbst R.S., Kelly K., Chansky K., Mack P.C., Franklin W.A., Hirsch F.R., Atkins J.N., Dakhil S.R., Albain K.S., Kim E.S., Redman M., Crowley J.J., Gandara D.R. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J. Clin. Oncol. 2010, 28:4747-4754.
147. Mascaux C., Peled N., Garg K., Kato Y., Wynes M.W., Hirsch F.R. Early detection and screening of lung cancer. Expert Rev. Mol. Diagn. 2010, 10:799-815.
148. Flanigan J., Deshpande H., Gettinger S. Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer. Biologics 2010, 4:237-243.
149. Neal J.W., Heist R.S., Fidias P., Temel J.S., Huberman M., Marcoux J.P., Muzikansky A., Lynch T.J., Sequist L.V. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. J. Thorac. Oncol. 2010, 5:1855-1858.
150. Price K.A., Azzoli C.G., Krug L.M., Pietanza M.C., Rizvi N.A., Pao W., Kris M.G., Riely G.J., Heelan R.T., Arcila M.E., Miller V.A. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J. Thorac. Oncol. 2010, 5:1623-1629.
151. Reckamp K., Gitlitz B., Chen L.C., Patel R., Milne G., Syto M., Jezior D., Zaknoen S. Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer. Cancer 2010, 117:809-818.
152. Rossi D., Dennetta D., Ugolini M., Catalano V., Alessandroni P., Giordani P., Baldelli A.M., Casadei V., Graziano F., Luzi Fedeli S. Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial. Target Oncol. 2010, 5:231-235.
153. Tan E., Gouvas N., Nicholls R.J., Ziprin P., Xynos E., Tekkis P.P. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg. Oncol. 2009, 18:15-24.
154. Traverso G., Shuber A., Levin B., Johnson C., Olsson L., Schoetz D.J., Hamilton S.R., Boynton K., Kinzler K.W., Vogelstein B. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N. Engl. J. Med. 2002, 346:311-320.
155. Wang Q., Chaerkady R., Wu J., Hwang H.J., Papadopoulos N., Kopelovich L., Maitra A., Matthaei H., Eshleman J.R., Hruban R.H., Kinzler K.W., Pandey A., Vogelstein B. Mutant proteins as cancer-specific biomarkers. Proc. Natl. Acad. Sci. USA 2011, 108:2444-2449.
156. Lance P. The cancer genome and diagnostic blood tests. Cancer Epidemiol. Biomarkers Prev. 2006, 15:2017-2018.
157. Cunningham D., Atkin W., Lenz H.-J., Lynch H.T., Minsky B., Nordlinger B., Starling N. Colorectal cancer. Lancet 2010, 375:1030-1047.
158. Asghar U., Hawkes E., Cunningham D. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin. Colorectal Cancer 2010, 9:274-281.
159. Webber E.M., Lin J.S., Evelyn P.W. Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction. PLoS Curr. 2010, 2.
160. Allen C.T., Lewis J.S., El-Mofty S.K., Haughey B.H., Nussenbaum B. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope 2010, 120:1756-1772.
161. Young R., Rischin D., Fisher R., McArthur G.A., Fox S.B., Peters L.J., Corry J., Lim A., Waldeck K., Solomon B. Relationship between epidermal growth factor receptor status, p16INK4A and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 2011, 20:1230-1237.
162. Chen Y., Peng C., Li D., Li S. Molecular and cellular bases of chronic myeloid leukemia. Protein Cell 2011, 1:124-132.